Symbols

PHAT

Phathom·NASDAQ

--(--)

PHAT Profile

Phathom Pharmaceuticals, Inc.

A biopharmaceutical company focused on developing novel treatments for gastrointestinal diseases and disorders

Industry

Pharmaceutical

Established Date

01/09/2018

Listing Date

10/25/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

371

Fiscal Year Ends

12-31

Website

www.phathompharma.com

Security Type

Common stock

Office address

100 Campus Drive , Suite 102 , Florham Park , New Jersey 07932

Business

Introduction

Phathom Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on January 9, 2018. The Company is a biopharmaceutical company focused on the development and commercialization of new therapies for the treatment of gastrointestinal diseases or GI diseases. The Company's approved products include VOQUEZNA, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK, all of which contain vonoprazan, an oral small molecule potassium ion competitive acid blocker (PCAB). PCAB is a new class of molecules that inhibit gastric acid secretion. VOQUEZNA is currently the only PCAB approved for sale in the United States.